Phase I Open Label study of Onconase [ranpirnase] administered on days 1 and 4 weekly for three consecutive weeks of a 28 day cycle in subjects with advanced solid malignancies

Trial Profile

Phase I Open Label study of Onconase [ranpirnase] administered on days 1 and 4 weekly for three consecutive weeks of a 28 day cycle in subjects with advanced solid malignancies

Not stated
Phase of Trial: Phase I

Latest Information Update: 14 Jan 2008

At a glance

  • Drugs Ranpirnase (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 14 Jan 2008 Status change
    • 18 Dec 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top